Psoriasis-Drug Pipeline Analysis and Market Forecasts to 2015

Oct. 8, 2010 - PRLog -- "Psoriasis-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global psoriasis market. The report identifies the key trends shaping and driving the dynamism in the global psoriasis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global psoriasis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis.
Psoriasis is estimated that the market to be worth $2.4 billion in 2008 with projected CAGR of 7.3% and projected market value to exceed $4.1 billion in 2015. The psoriasis disease market is forecast to show high growth. This growth will be driven or supported by the increased prescription rate and uptake of biologics, more emerging therapies and diverse treatment options that will be available for patients in the near future. Barriers for the psoriasis market exist in terms of low diagnosis rate. The psoriasis market has relatively high unmet need largely driven by the poor safety profile of existing products.

There are over 125 molecules in various stages of the pipeline. Voclosporin, ABT-874, CF-10 are some of the late stage pipeline molecules. Orencia, Cimzia, Apremilast and INCB18424 are some of the promising therapies in the Phase II stage of the pipeline. These pipeline molecules differ in their target of action from the existing therapies. Patient perception of disease severity drives treatment-seeking behavior in the psoriasis market. New therapeutic options targeting specific mechanisms are set to reshape the psoriasis therapy. However, the current biologics have not undermined first-line topical therapy and hence there exists intensified competition between the current therapeutics and the emerging therapies. The pipeline has seen an increase in the development of emerging therapies like biologics as they have the ability to change the natural course of the disease. Emerging therapies have gained a positive perception among physicians in the maintenance of remission. There is likely to be a tremendous increase in the prescription of biologics due to increased awareness and also promising safety and efficacy results of promising therapies. The emerging therapies are likely to crowd the market and there is the possibility of price war.

The current competition in the psoriasis market is becoming intense due to the increased entry of biologics. It projects that Immunex Corporation, Abbott laboratories. Biogen Idec and Centocor will remain the leading competitiors of the global psoriasis biologics market. Compared to other autoimmune disease markets, this market has witnessed a greater entry of biologics. Though only a small segment of people tend to use biologics, their launch has increased competition in the psoriasis disease market. Amgen and Wyeth's Enbrel is the market leader in the psoriasis disease market. It is followed by Abbott's Humira, Leo Pharma and Warner Chiclott's Dovonex, Centocor's Remicade, Genentech's Raptiva, Novartis's Neoral (generic), followed by Allergan's Tazorac, Biogen Idec's Fumaderm and Biogen Idec and Astellas Pharma's Amevive.

Scope of the report includes:
-Annualized global psoriasis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include TNF-alpha inhibitors, interleukin inhibitors, vitamin D3 analogues, topical corticosteroids, enzyme inhibitors, immunomodulatory drugs, anti-inflammatory drugs, T cell modulators and ion channel modulators.

Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figuresm
2 Global Psoriasis Market: Market Characterization
2.1 Overview
2.2 Psoriasis Market Size
2.3 Psoriasis Market Forecast and CAGR
2.4 Drivers and Barriers for Psoriasis Market
2.4.1 Drivers for Psoriasis Market
2.4.2 Barriers for Psoriasis Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Psoriasis Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in Psoriasis Market
3.3.1 Enbrel (etanercept)
3.3.2 Humira (adalimumab)
3.3.3 Amevive (alefacept)
3.3.4 Remicade (infliximab)
3.3.5 Stelara (ustekinumab, CNTO1275)
3.3.6 Clobex (clobetasol propionate)
3.3.7 Tazorac (tazarotene, Avage)
3.3.8 Dovonex (calcipotriene)
3.4 Other Marketed Products for Psoriasis (Generics)
3.4.1 Neoral (cyclosporine)
3.5 Key Takeaway
4 Psoriasis Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework  
4.2.2 Psoriasis Therapeutics-Promising Drugs under Clinical Development
4.3 Molecule Profile for Promising Drugs for Psoriasis under Clinical Development
4.3.1 Voclosporin (LX211, LUVENIQ, ISA-247)
4.3.2 ABT-874 (J-695, Briakinumab)
4.3.3 CF-101
4.3.4 Orencia (abatacept, CTLA4-Ig, BMS-188667)
4.3.5 Cimzia (CDP870 certolizumab pegol)
4.3.6 Apremilast (CC10004, ACR20)
4.3.7 INCB18424
4.4 Psoriasis Therapeutics Market-Clinical Pipeline by Mechanism of Action
4.5 Psoriasis Pipeline-Pipeline by Clinical Phases of Development
4.5.1 Psoriasis Therapeutics-Phase III Clinical Pipeline
4.5.2 Psoriasis Therapeutics-Phase II Clinical Pipeline
4.5.3 Psoriasis Therapeutics-Phase I Clinical Pipeline
4.5.4 Psoriasis Therapeutics-Preclinical Pipeline
4.5.5 Psoriasis Therapeutics-Discovery Pipeline
4.6 Discontinued/Suspended Drug for Psoriasis
4.7 Key Takeaway
5 Psoriasis Market: Implications for Future Market Competition
6 Psoriasis Market: Future Players in the Psoriasis Market
6.1 Introduction
6.1.1 Isotechnika
6.1.2 Overview
6.1.3 Autoimmune and Dermatology Disease Portfolio
6.1.4 Psoriasis Product Portfolio
6.2 Can-Fite BioPharma
6.2.1 Overview
6.2.2 Autoimmune and Dermatology Disease Portfolio
6.2.3 Psoriasis Product Portfolio
6.3 UCB
6.3.1 Overview
6.3.2 Autoimmune and Gastrointestinal Disease Portfolio
6.3.3 Psoriasis Product Portfolio
6.4 Celgene Corporation
6.4.1 Overview
6.4.2 Autoimmune and Dermatology Disease Portfolio
6.4.3 Psoriasis Product Portfolio
6.5 Incyte
6.5.1 Overview
6.5.2 Autoimmune and Dermatology Disease Portfolio
6.5.3 Psoriasis Product Portfolio
6.6 GlaxoSmithKline plc
6.6.1 Overview
6.6.2 Psoriasis Product Portfolio
6.7 Bristol-Myers Squibb
6.7.1 Overview
6.7.2 Psoriasis Product Portfolio
6.8 Leo Pharma
6.8.1 Overview
6.9 Novartis
6.9.2 Psoriasis Product Portfolio
6.10 Abbott Laboratories
6.10.1 Overview
6.10.2 Psoriasis Product Portfolio
7 Psoriasis Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Tables
1.1 List of Tables
Table 1: Global Psoriasis Therapeutics Market, Revenue Forecasts ($m), 2000-2008
Table 2: Global Psoriasis Therapeutics Market, Revenue Forecasts ($m), 2008-2015
Table 3: Major Marketed Products Comparison in the Psoriasis Market, 2009
Table 4: Psoriasis Therapeutics-Most Promising Drugs Under Clinical Development, 2009
......

List of Figures
1.2 List of Figures
Figure 1: Global Psoriasis Therapeutics Market, Revenue ($m), 2000-2015
Figure 2: Opportunity and Unmet Need in the Psoriasis Market, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Psoriasis, 2009
......

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.